Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial

Authors

Dong Xie (ORCID: https://orcid.org/0000-0001-9858-3782)
Vijay Harypursat (ORCID: https://orcid.org/0000-0001-7423-6786)
Yihong Zhou
Yaokai Chen (ORCID: https://orcid.org/0000-0003-3403-9782)
Kun He (ORCID: https://orcid.org/0000-0002-0587-2313)
Xiaofeng Li (ORCID: https://orcid.org/0000-0001-6330-4931)
Yi Li (ORCID: https://orcid.org/0000-0002-3875-3513)
Yuanyuan Chen (ORCID: https://orcid.org/0000-0002-9655-7828)
Qingxia Zhao
Min Wang
Yuanyuan Qin
Xia Liu

Institutions

The First Hospital of Changsha (CN)
Frontier Environmental Technology (United States) (US)
The Sixth People's Hospital of Zhengzhou (CN)
Chongqing Public Health Medical Center (CN)

Publication Details

Journal: BMC Infectious Diseases
Published: 2026-03-28
DOI: https://doi.org/10.1186/s12879-026-12987-3
Primary Topic: HIV/AIDS drug development and treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial

Dong Xie, Vijay Harypursat, Yihong Zhou, Yaokai Chen et al.

Mar 28, 2026

BMC Infectious Diseases

HIV/AIDS drug development and treatment

article

Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial

Dong Xie, Vijay Harypursat, Yihong Zhou, Yaokai Chen, Kun He, Xiaofeng Li, Yi Li, Yuanyuan Chen, Qingxia Zhao, Min Wang, Yuanyuan Qin, Xia Liu

March 28, 2026article en

Abstract

No abstract available for this paper.

BMC Infectious Diseases

The First Hospital of Changsha (CN), Frontier Environmental Technology (United States) (US), The Sixth People's Hospital of Zhengzhou (CN), Chongqing Public Health Medical Center (CN)

Good health and well-being

Openalex Percentile: Top 4%

HIV/AIDS drug development and treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.